Leveraging over a decade of the co-founders’ extensive research on NBD1, the company is advancing a pipeline of novel small molecules engineered to correct the defects caused by the F508del genetic ...
Leveraging over a decade of the co-founders' extensive research on NBD1, the company is advancing a pipeline of novel small molecules engineered to correct the defects caused by the F508del ...